New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT02326974
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving two targeted drugs, T-DM1 and pertuzumab, before surgery can completely eliminate early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the drugs for 18 weeks, then undergo surgery. The main goal is to see how many have no cancer left at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
T-DM1 (Kadcyla) and pertuzumab (Perjeta)
What this could lead to
If successful, this combination could become a standard preoperative treatment, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is a phase II trial with 164 participants, so results are still preliminary. The treatment may not work for everyone, especially those with mixed HER2 levels in their tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Tennessee Oncology/Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States